Bladder Cancer,Genitourinary Cancer KEYNOTE-676 Study Shows Improved Efficacy and Safety for Non-Muscle Invasive Bladder Cancer Treatment Apr 20, 2023
Bladder Cancer,Genitourinary Cancer COXEN: Revolutionizing Chemotherapy Treatment for Bladder Cancer Patients Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Oral Infigratinib for Invasive Urothelial Carcinoma with FGFR3 Genetic Alterations: A Promising Therapy Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Targeting Molecular Alterations in Advanced Solid Tumors: My Pathway Study Phase 2A Study Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Safety and Efficacy of sEphB4-HSA+Pembrolizumab in Patients with Solid Tumors: Phase 2 Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer EV for the Treatment of LA/mUC Bladder Cancer: EV-201 in Phase 2 Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Evaluating the Efficacy of Cabozantinib and Avelumab in Metastatic Urothelial Cancer: MAIN-CAV in Phase 3 Trial Apr 20, 2023
Bladder Cancer,Genitourinary Cancer Neoadjuvant Atezolizumab in MIBC Patients Ineligible for Cisplatin: ABACUS in Phase 2 Trial Apr 20, 2023
